Skip to main content

Table 7 Association between different parameters and median EFS rate in osteosarcoma patients treated with cisplatin combinations

From: The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients

The studied parameter Median EFS time in years Log rank
Tumor location Arm 1.49 0.477
Femur 1.70
Tibia 2.29
Others 1.73
Presence of metastasis No metastasis 2.04 0.071
With metastasis 0.750
Gender Male 2.04 0.289
Female 1.16
Histological subtypes Conventional 2.04 0.039
Variant 1.00
Type of chemotherapy MAP 1.73 0.432
Cisplatin & doxorubicin 1.42
Others 3.07
Response Poor response 1.42 0.189
Good response 3.07